Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Taurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 10/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurine SCHEMBL4898461 | 1.00 | LMNA (0.54) | LMNASLC6A6CYP2C19BLMAPP | |
| Taurine SCHEMBL3799348 | 0.94 | LMNA (0.61) | LMNASLC6A6CYP2C19BLMAPP | |
| Alanine SCHEMBL11693939 | 0.86 | GLRA1 (0.48) | GLRA1SLC6A9OR51E2GABRR1PMP22 | |
| Alanine SCHEMBL50127 | 0.86 | GLRA1 (0.48) | GLRA1SLC6A9OR51E2GABRR1PMP22 | |
| Taurine SCHEMBL1526984 | 0.85 | LMNA (0.74) | LMNASLC6A6CYP2C19BLMAPP | |
| Taurine SCHEMBL22774725 | 0.85 | LMNA (0.74) | LMNASLC6A6CYP2C19BLMAPP | |
| Taurine SCHEMBL27979344 | 0.82 | LMNA (0.61) | LMNASLC6A6CYP2C19BLMAPP | |
| Taurine SCHEMBL30443868 | 0.82 | LMNA (0.61) | LMNASLC6A6CYP2C19BLMAPP | |
| Alanine SCHEMBL25189736 | 0.81 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1ENPEP | |
| Alanine SCHEMBL8383645 | 0.81 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104203269-A | Use of immunomodulators for treating cancer | GREGORY DANIEL TYREE JR | 2014-12-10 | — | — | CN | disclosed |
| WO-2013123478-A1 | USE OF IMMUNOMODULATORS FOR THE TREATMENT OF CANCER | ZOR PHARMACEUTICALS LLC (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8338383-B1 | Use of immunomodulators for the treatment of cancer | GREGORY JR DANIEL TYREE (US) | 2012-12-25 | — | — | US | disclosed |
| US-8236354-B1 | Use of immunomodulators for the treatment of cancer | ZOR Pharmaceuticals, LLC (US) | 2012-08-07 | — | — | US | disclosed |
| US-20080279957-A1 | Immunomodulating compositions from bile | LORUS THERAPEUTICS INC. | 2008-11-13 | — | — | US | disclosed |
| US-20040101569-A1 | Immunomodulating compositions from bile | LORUS THERAPEUTICS INC. | 2004-05-27 | — | — | US | disclosed |
| US-6596319-B2 | Such as various cancers, by administering low molecular weight compounds of following properties: extractable from bile of an animal, stimulates monocytes and macrophages, modulates tumor necrosis factor production, not endotoxin | LORUS THERAPEUTICS INC. (CA) | 2003-07-22 | — | — | US | disclosed |
| EP-0717631-B1 | IMMUNOMODULATING COMPOSITIONS FROM BILE | LORUS THERAPEUTICS INC (CA) | 2003-07-09 | — | — | EP | disclosed |
| US-6551623-B1 | Pure and potent extract from bovine bile, the composition capable of stimulating monocytes and/or macrophages in vitro, and capable modulating tumor necrosis factor production; nontoxicity to human blood cells; treating cancer, AIDS | LORUS THERAPEUTICS INC. (CA) | 2003-04-22 | — | — | US | disclosed |
| US-6280774-B1 | EXTRACTION OF BILE FROM ANIMALS, STIMULATING MONOCYTES AND MACROPHAGES AND MODULATING TUMOR NECROSIS FACTOR PRODUCTION | LORUS THERAPEUTICS INC. (CA) | 2001-08-28 | — | — | US | disclosed |
| US-20010009680-A1 | Immunomodulating compositions for treatment of immune system disorders | ERIN MILLS BIOTECH INC. (CA) | 2001-07-26 | — | — | US | disclosed |
| WO-1998052585-A1 | IMMUNOMODULATING, BILE-DERIVABLE COMPOSITIONS FOR THE TREATMENT OF VIRAL DISORDERS | LORUS THERAPEUTICS INC. (CA) | 1998-11-26 | — | — | WO | disclosed |
| CN-1182368-A | Immanomodulating compositions from bile for treatment of immune system disorders | IMUTEC CORP (CA) | 1998-05-20 | — | — | CN | disclosed |
| EP-0814821-A1 | IMMUNOMODULATING COMPOSITIONS FROM BILE FOR THE TREATMENT OF IMMUNE SYSTEM DISORDERS | Imutec Pharma Inc. (CA) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028175-A1 | IMMUNOMODULATING COMPOSITIONS FROM BILE FOR THE TREATMENT OF IMMUNE SYSTEM DISORDERS | IMUTEC PHARMA INC. (CA) | 1996-09-19 | — | — | WO | disclosed |
| EP-0717631-A1 | IMMUNOMODULATING COMPOSITIONS FROM BILE | IMUTEC CORPORATION (CA) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007089-A1 | IMMUNOMODULATING COMPOSITIONS FROM BILE | IMUTEC CORPORATION (CA) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101569-A1 | Immunomodulating compositions from bile | IL2, IFNG, IL4 | LMNA 4095/4885SLC6A6 3693/4885CYP2C19 4681/4885 |
| US-20010009680-A1 | Immunomodulating compositions for treatment of immune system disorders | IFNG, IL2, CD14 | LMNA 4129/4885SLC6A6 3993/4885CYP2C19 4873/4885 |
| US-20080279957-A1 | Immunomodulating compositions from bile | IL2, IFNG, IL4 | LMNA 4095/4885SLC6A6 3693/4885CYP2C19 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.